T-cell therapy after hematopoietic stem cell transplantation

Current Opinion in Hematology

Volumn 14, Issue 6, 2007, Pages 616-624

  Kennedy Nasser, Alana A ^a   Brenner, Malcolm K ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Cytotoxic T lymphocyte; Immunotherapy; Regulatory T cell; Suicide genes

Indexed keywords

TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CLONAL ANERGY; CYTOTOXIC T LYMPHOCYTE; GENETIC TRANSFECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFUSION; LEUKEMIA; NATURAL KILLER CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SUICIDE GENE; T CELL DEPLETION; T LYMPHOCYTE;

ANTIGENS, FUNGAL; ANTIGENS, NEOPLASM; ANTIGENS, VIRAL; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; T-LYMPHOCYTES;

EID: 34848865393     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3282ef615a     Document Type: Review

References (59)

1. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response? Bone Marrow Transplant 1995; 15:591-594.
2. Choi SJ, Lee JH, Lee JH, et al. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study. Bone Marrow Transplant 2005; 36:163-169.
3. Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004; 103:1548-1556.
4. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365:1934-1941.
5. + cell dose, GVHD and disease response. Bone Marrow Transplant 2004; 34:511-514.
6. Amrolia PJ, Muccioli-Casadei G, Huls H, et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006; 108:1797-1808. This paper demonstrates the ability of adoptively transferred CD25-depleted T cells to improve immune reconstitution following HSCT.
7. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002; 360:130-137.
8. Hartwig UF, Nonn M, Khan S, et al. Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes. Bone Marrow Transplant 2006; 37:297-305.
9. + cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant 2004; 34:123-128.
10. Rooney CM, Roskrow MA, Suzuki N, et al. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol 1998; 9 (Suppl 5):S129-S132.
11. Gottschalk S, Heslop HE, Rooney CM. Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res 2002; 84:175-201.
12. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95:807-814.
13. Heslop HE. Biology and treatment of epstein-barr virus-associated non-hodgkin lymphomas. Hematology Am Soc Hematol Educ Program 2005; 260-266.
14. Bollard CM, Huls MH, Buza E, et al. Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. Clin Lymphoma Myeloma 2006; 6:342-347. This paper highlights the role of using adoptive immunotherapy with latent membrane protein-2 specific CTLs to treat relapsed EBV-positive lymphomas after HSCT.
15. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333:1038-1044.
16. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992; 257:238-241.
17. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202:379-386.
18. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99:3916-3922.
19. + T cells according to IFN-gamma secretion for adjuvant immunotherapy. Exp Hematol 2004; 32:282-289.
20. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12:1160-1166. This paper emphasizes a new technique for generating multivirus specific CTLs that are effective in vivo at preventing or treating viral infections following HSCT.
21. Passweg JR, Tichelli A, Meyer-Monard S, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004; 18:1835-1838.
22. Bonini C, Bondanza A, Perna SK, et al. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther 2007; 15:1248-1252.
23. Traversari C, Marktel S, Magnani Z, et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 2007; 109:4708-4715. This paper addresses one of the pitfalls of thymidine kinase suicide gene therapy, specifically the immunogenicity of the thymidine kinase suicide gene.
24. Straathof KC, Pule MA, Yotnda P, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005; 105:4247-4254.
25. Wehler TC, Nonn M, Brandt B, et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood 2007; 109:365-373.
26. Amrolia PJ, Mucioli-Casadei G, Huls H, et al. Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation. Cytotherapy 2005; 7:116-125.
27. Solomon SR, Mielke S, Savani BN, et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005; 106:1123-1129.
28. Amrolia PJ, Muccioli-Casadei G, Yvon E, et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 2003; 102:2292-2299.
29. Solomon SR, Tran T, Carter CS, et al. Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. Cytotherapy 2002; 4:395-406.
30. + T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease. Bone Marrow Transplant 2004; 34:987-994.
31. + T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Exp Hematol 2004; 32:1097-1102.
32. + T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens. Bone Marrow Transplant 2005; 35:247-252.
33. Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999; 340:1704-1714.
34. high regulatory T cells. Blood 2004; 104:895-903.
35. + T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193:1285-1294.
36. high regulatory cells in human peripheral blood. J Immunol 2001; 167:1245-1253.
37. + regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196:389-399.
38. Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108:1291-1297. This paper illustrates that donor grafts with high FoxP3 T reg cell content correlates with lower rates of GvHD following HSCT.
39. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92:1549-1555.
40. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 362:1375-1377.
41. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2:551-555.
42. Kleihauer A, Grigoleit U, Hebart H, et al. Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells. Br J Haematol 2001; 113:231-239.
43. + T lymphocytes using dendritic cells pulsed with a human leucocyte antigen A*0201- restricted peptide. Br J Haematol 2001; 113:479-482.
44. Peggs K, Verfuerth S, Mackinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood 2001; 97:994-1000.
45. Ramadan G. Generation of Aspergillus-specific T lymphocytes with cytotoxic activity. Egypt J Immunol 2004; 11:59-70.
46. Ramadan G, Konings S, Kurup VP, Keever-Taylor CA. Generation of Aspergillus- and CMV-specific T-cell responses using autologous fast DC. Cytotherapy 2004; 6:223-234.
47. Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005; 106:4397-4406.
48. Bissinger AL, Rauser G, Hebart H, et al. Isolation and expansion of human cytomegalovirus- specific cytotoxic T lymphocytes using interferon-gamma secretion assay. Exp Hematol 2002; 30:1178-1184.
49. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006; 134:64-76. This paper addresses a technique that allows the adoptive transfer of adenovirus-specific CTLs following HSCT, with clinical improvement seen in adenovirus following infusion.
50. Chatziandreou I, Gilmour KC, McNicol AM, et al. Capture and generation of adenovirus specific T cells for adoptive immunotherapy. Br J Haematol 2007; 136:117-126. This paper discusses a technique for the generation of adenovirus CTLs.
51. Dickinson AM, Wang XN, Sviland L, et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002; 8:410-414.
52. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003; 100:2742-2747.
53. Di TS, Zino E, Mazzi B, et al. Therapeutic and diagnostic applications of minor histocompatibility antigen HA-1 and HA-2 disparities in allogeneic hematopoietic stem cell transplantation: a survey of different populations. Biol Blood Marrow Transplant 2006; 12:95-101. This paper highlights the role of mHA disparities in patients following HSCT.
54. Riddell SR, Bleakley M, Nishida T, et al. Adoptive transfer of allogeneic antigen-specific T cells. Biol Blood Marrow Transplant 2006; 12:9-12.
55. Warren EH, Tykodi SS, Murata M, et al. T-cell therapy targeting minor histocompatibility Ags for the treatment of leukemia and renal-cell carcinoma. Cytotherapy 2002; 4:441.
56. + T-cell responses to WT-1 after HSCT with GvL effect.
57. Savani BN, Rezvani K, Mielke S, et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2006; 107:1688-1695.
58. Marktel S, Magnani Z, Ciceri F, et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 2003; 101:1290-1298.
59. Thomis DC, Marktel S, Bonini C, et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 2001; 97:1249-1257.